ArticleJournal of clinical pathology2001
The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.
Article in Journal of clinical pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 53 citations in OpenAlex.
- A patient with paraganglioma undergoing laparoscopic resection: A case report.Clinical case reports · 2021Article
- VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma.Histology and histopathology · 2021Article
- Article
- Article
- Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.Endocrine pathology · 2017Review
- Molecular markers of paragangliomas/pheochromocytomas.Oncotarget · 2017Review
- Adrenal oncocytic phaeochromocytoma with putative adverse histologic features: a unique case report and review of the literature.Endocrine pathology · 2014Review
- Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.Langenbeck's archives of surgery · 2012Review
- MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?Virchows Archiv : an international journal of pathology · 2011Article
- Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma.Neoplasia (New York, N.Y.) · 2010Article
- hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features.International journal of colorectal disease · 2008Article
- Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators.Endocrine pathology · 2005Article
- Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.Endocrine pathology · 2003Review
- Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPhaeochromocytomas and paragangliomas are uncommon. The aims of this study were to analyse the characteristics and the possible roles of p53, Rb, and mdm2 alterations in these tumours.
methodsThe clinicopathological features of 65 patients (31 men, 34 women) with phaeochromocytomas or paragangliomas were analysed. The tumours were studied for the expression of p53, Rb, and mdm2 by immunohistochemical methods.
resultsThirty nine of the patients had phaeochromocytomas and 26 had paragangliomas. Bilateral tumours were noted in eight of the patients and malignant tumours were seen in 13. Paragangliomas were often small, non-functional, and presented incidentally, whereas phaeochromocytomas were usually large, functional, and symptomatic. p53 overexpression, loss of Rb expression, and mdm2 overexpression were seen in four, 43, and 37 of the patients, respectively. Three of the four patients with p53 overexpression had bilateral tumours. Loss of Rb expression was often found in phaeochromocytomas, whereas mdm2 overexpression was more frequently seen in paragangliomas. The 10 year survival rate of patients with malignant tumours was 45%. Two patients died of tumour metastases more than 10 years after resection of the primary tumours.
conclusionsPhaeochromocytomas and paragangliomas had distinctive clinical features and genetic alterations. The prognosis of patients with these tumours was related to the malignant potential. p53 overexpression, more common in bilateral phaeochromocytomas and paragangliomas, could be a marker for this tumour subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.